Erratum : Debates in allergy medicine: specific immunotherapy efficiency in children with atopic dermatitis (World Allergy Organization Journal (2016) 9 (38) DOI: 10.1186/s40413-016-0106-3);Debates in allergy medicine: Specific immunotherapy efficiency in children with atopic dermatitis

World Allergy Organization Journal

Volumn 9, Issue 1, 2016, Pages 1-1

  Slavyanakaya, Tatiana A ^a,b   Derkach, Vladislava V ^b,c   Sepiashvili, Revaz I ^a,b  

^a PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

^b Institute of Immunophysiology   (Russian Federation)

^c PACIFIC STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Aeroallergen; Allergen specific immunotherapy; Atopic dermatitis; Children; Clinical efficacy; Subcutaneous specific immunotherapy; Sublingual specific immunotherapy

Indexed keywords

ALUMINUM HYDROXIDE; EOSINOPHIL CATIONIC PROTEIN; GAMMA INTERFERON; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; PLACEBO; POLLEN ANTIGEN;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC REACTION; ALLERGIC RHINITIS; ARTICLE; ATOPIC DERMATITIS; CHILD; DERMATOPHAGOIDES; DRUG EFFICACY; GRASS POLLEN; HUMAN; IMMUNOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; SCORING SYSTEM; SEVERITY SCORING OF ATOPIC DERMATITIS; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY;

EID: 84963979858     PISSN: None     EISSN: 19394551     Source Type: Journal    
DOI: 10.1186/s40413-016-0128-x     Document Type: Erratum

References (96)

1. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8:17.
2. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011;127:18-27.
3. Akdis CA, Akdis M. Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. J Clin Invest. 2014;124:4678-80.
4. Akdis CA. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med. 2012;18(5):736-49.
5. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133:621-31.
6. Akkoc T, Akdis M, Akdis CA. Update in the mechanisms of allergen-specific immunotherapy. Allergy Asthma Immunol Res. 2011;3:11-20.
7. Arkwright PD, Stafford JC, Sharma V. Atopic dermatitis in children. J Allergy Clin Immunol Pract. 2014;bv2(4):388-95.
8. Avgerinou G. Atopic dermatitis: new immunologic aspects. Int J Dermatol. 2008;47:219-24.
9. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132(1):110-7.
10. Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010;125:4-13.
11. Bouton C, Ducommun J. Specific immunotherapy design questions. Rev Med Suisse. 2009;5(199):832-6.
12. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, Nelson H, Akdis CA. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288-96.
13. Bussmann C, Böckenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol. 2006;118(6):1292-8.
14. Bussmann C, Maintz L, Hart J, Allam JP, Vrtala S, Chen KW, Bieber T, Thomas WR, Valenta R, Zuberbier T, Sager A, Novak N. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy. 2007;37(9):1277-85.
15. Casset A, Mari A, Purohit A, Resch Y, Weghofer M, Ferrara R, Thomas WR, Alessandri C, Chen KW, de Blay F, Valenta R, Vrtala S. Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts. Int Arch Allergy Immunol. 2012;159(3):253-62.
16. Cadario G, Galluccio AG, Pezza M, Appino A, Milani M, Pecora S, Mastrandrea F. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. Curr Med Res Opin. 2007;23(10):2503-6.
17. Calderon MA, Gerth van Wijk R, Eichler I, Matricardi PM, Varga EM, Kopp MV, Eng P, Niggemann B, Nieto A, Valovirta E, Eigenmann PA, Pajno G, Bufe A, Halken S, Beyer K, Wahn U. Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement. Pediatr Allergy Immunol. 2012;23:300-6.
18. 2LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J. 2013;6(1):17.
19. Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, Bousquet J, Calderón M, Compalati E, Durham SR, van Wijk RG, Larenas-Linnemann D, Nelson H, Passalacqua G, Pfaar O, Rosário N, Ryan D, Rosenwasser L, Schmid-Grendelmeier P, Senna G, Valovirta E, Van Bever H, Vichyanond P, Wahn U, Yusuf O. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6.
20. Casale T, Canonica GW, Bousquet J, Cox L, Nelson H, Passalacqua G. Recommendations for appropriate sublingual immunotherapy (SLIT) clinical trials. J Allergy Clin Immunol. 2009;124:665-70.
21. Choi JS, Ryu HR, Yoon CH. Treatment of patients with refractory atopic dermatitis sensitized to house dust mites by using sublingual allergen immunotherapy. Ann Dermatol. 2015;27(1):82-6.
22. Compalati E, Braido F, Canonica GW. Sublingual immunotherapy: recent advances. Allergol Int. 2013;62(4):415-23.
23. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009;64:1570-9.
24. Compalati E, Rogkakou A, Passalacqua G, Canonica GW. Evidences of efficacy of allergen immunotherapy in atopic dermatitis: an updated review. Curr Opin Allergy Clin Immunol. 2012;12(4):427-33.
25. Czarnecka-Operacz M, Silny W. Specific immunotherapy in atopic dermatitis-Four-year treatment in different age and airborne allergy type subgroups. Acta Dermatovenerol Croat. 2006;14(4):230-40.
26. Darsow U, Forer I, Ring J. Allergen-specific immunotherapy in atopic eczema. Curr Allergy Asthma Rep. 2011;11(4):277-83.
27. Darsow U. Allergen-specific immunotherapy for atopic eczema: updated. Curr Opin Allergy Clin Immunol. 2012;12(6):665-9.
28. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, Berger AE, Zhang K, Vidyasagar S, Yoshida T, Boguniewicz M, Hata T, Schneider LC, Hanifin JM, Gallo RL, Novak N, Weidinger S, Beaty TH, Leung DY, Barnes KC, Beck LA. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127:773-86.
29. Derkach V, Slavyanskaya T. Atopic dermatitis in children: treatment and quality of life. Journal of the National Medical and Surgical Center named NI Pirogov. 2013;3(8):86-8 [in Russian].
30. Derkach V, Slavyanskaya T. Combined immunotherapy in children with atopic dermatitis: rationale for application. Allergy. Asthma & Immunophysiology: from Genes to Clinical Management. Medimond s.r.l. - Monduzzi Editore.- International Proceedings. 2014. p. 63-7. http://www.medimond.com/proceedings/moreinfo/20140426-index.pdf.
31. Derkach V, Slavyanskaya T. Comparative analysis of pharmacoeffectiveness of various programs of immunotropic therapy of children with atopic dermatitis. Allergy, Asthma & Immunophysiology: from basic sciences to clinical management. Medimond s.r.l. - Monduzzi Editore.- International Proceedings. 2013. p. 43-5. http://www.medimond.com/proceedings/moreinfo/20130427-index.pdf.
32. Derkach V, Slavyanskaya T. Cost-effectiveness of immunotropic therapy for children with atopic dermatitis. World Allergy Organization J. 2013;6 Suppl 1:228.
33. Derkach V., Slavyanskaya T. Severe atopic dermatitis and quality of life in children during background therapy. J Allergy Clin Immunol. 2013;Supplement: AB35: 131(2): Ref. 129.
34. Derkach V, Slavyanskaya T. Comparative characteristic of effectiveness of immunotherapy of children with atopic dermatitis. Allergy, Asthma & Immunophysiology: Recent Advances in understanding and Management. Ed. R. Sepiashvili. Medimond S.r.l. -Monduzzi Editore International Proceedings. 2015. p. 45-9. http://www.monduzzi.com/proceedings/moreinfo/20150426-index.pdf
35. Derkach V, Slavyanskaya T. Effectiveness of immunotherapy in children with atopic dermatitis. Int J on Immunorehabilitation. 2015;17(1):9-12.
36. Di Rienzo V, Cadario G, Grieco T, Galluccio AG, Caffarelli C, Liotta G, Pecora S, Burastero SE. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study. Ann Allergy Asthma Immunol. 2014;113(6):671-73.
37. Frati F, Ridolo E, Fuiano N, Barberi S, Dell'Albani I, Landi M, Ricciardi L, Scala G, Incorvaia C. Safety of sublingual immunotherapy in children. Expert Opin Drug Saf. 2014;13(7):947-53.
38. Galli E, Chini L, Nardi S, Benincori N, Panei P, Fraioli G, et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergol Immunopathol (Madr). 1994;22:18-22.
39. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy. 1992;22:440-46.
40. Gutgesell C, Heise S, Seubert S, Seubert A, Domhof S, Brunner E, Neumann C. Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis. Br J Dermatol. 2001;145(1):70-4.
41. Hata TR, Gallo R. Antimicrobial peptides, skin infections, and atopic dermatitis. Semin Cutan Med Surg. 2008;27:144-50.
42. Henszel Ł, Kuźna-Grygiel W. House dust mites in the etiology of allergic diseases. Ann Acad Med Stetin. 2006;52(2):123-7.
43. Incorvaia C, Mauro M, Cappelletti T, Pravettoni C, Leo G, Riario-Sforza GG. New applications for sublingual immunotherapy in allergy. Recent Pat Inflamm Allergy Drug Discov. 2009;3(2):113-17.
44. Jutel M, Van de Veen W, Agache I, Azkur KA, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development. Allergol Int. 2013;62(4):425-33.
45. Kaufman HS, Roth HL. Hyposensitization with alum precipitated extracts in atopic dermatitis: a placebo-controlled study. Ann Allergy. 1974;32:321-30.
46. Kim J, Lee S, Woo SY, Han Y, Lee JH, Lee IY, Lim IS, Choi ES, Choi BW, Cheong HK, Lee SI, Ahn K. The indoor level of house dust mite allergen is associated with severity of atopic dermatitis in children. J Korean Med Sci. 2013;28(1):74-9.
47. Larenas-Linnemann D. Certainties and doubts about sublingual and oral immunotherapy in children. Curr Opin Allergy Clin Immunol. 2009;9(6):558-67.
48. Lee J, Park CO, Lee KH. Specific immunotherapy in atopic dermatitis. Allergy Asthma Immunol Res. 2015;7(3):221-9.
49. Leung TN, Hon KL. Eczema therapeutics in children: what do the clinical trials say? Hong Kong Med J. 2015;21(3):251-60.
50. Leung DYM, Eichenfield LF, Boguniewicz M. Atopic dermatitis (atopic eczema). in: Fitzpatrick's Dermatology in General Medicine. 7th ed. McGraw-Hill. New York. 2008;1:146-58.
51. Mastrandrea F, Serio G, Minelli M, Minardi A, Scarcia G, Coradduzza G, Parmiani S. Specific sublingual immunotherapy in atopic dermatitis. Results of a 6-year follow-up of 35 consecutive patients. Allergol Immunopathol (Madr). 2000;28(2):54-62.
52. Mastrandrea F. The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis. Am J Clin Dermatol. 2004;5(5):281-94.
53. Nahm DH, Lee ES, Park HJ, Kim HA, Choi GS, Jeon SY. Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex. Int Arch Allergy Immunol. 2008;146(3):235-40.
54. Nankervis H, Pynn EV, Boyle RJ, Rushton L, Williams HC, Hewson DM, Platts-Mills T. House dust mite reduction and avoidance measures for treating eczema. Cochrane Database Syst Rev. 2015;1, CD008426.
55. Novak N, Thaci D, Hoffmann M, Fölster-Holst R, Biedermann T, Homey B, Schaekel K, Stefan JA, Werfel T, Bieber T, Sager A, Zuberbier T. Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract-a new therapeutic option for patients with atopic dermatitis. Int Arch Allergy Immunol. 2011;155(3):252-6.
56. Novak N, Werfel T. Specific immunotherapy and atopic dermatitis. What is new? Hautarzt. 2011;62(9):650-6.
57. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol. 2007;7:542-46.
58. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, Phase Three Study Group ISAAC. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124:1251-8.
59. O'Regan GM, Sandilands A, McLean WH, Irvine AD. Filaggrin in atopic dermatitis. J Allergy Clin Immunol. 2009;124:R2-6.
60. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120(1):164-70.
61. Pajno GB, Peroni DG, Barberio G, Boner AL. Efficacy of sublingual immunotherapy in asthma and eczema. Chem Immunol Allergy. 2003;82:77-88.
62. Pasalaqua G. Recommendations for appropriate sublingual immunotherapy clinical trials. World Allergy Organ J. 2014;7:21. http://www.waojournal.org/content/7/1/21.
63. Passalacqua G, Baena Cagnani C, Bousquet J, Canonica GW, Cox L, Durham S, Larenas Linnemann D, Ledford D, Potter P, Rosario N, Wallace D, Lockey RF. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol. 2013;132:93-8.
64. Passalacqua G, Compalati E, Canonica GW. Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper. World Allergy Organ J. 2010;3(7):216-9.
65. Passalacqua G, Compalati E, Canonica GW. Sublingual immunotherapy: other indications. Immunol Allergy Clin North Am. 2011;31(2):279-87.
66. Passalacqua G. Recommendations for appropriate sublingual immunotherapy clinical trials. World Allergy Organ J. 2014;7(1):21.
67. Peters AS, Kellberger J, Vogelberg C, et al. Prediction of the incidence, recurrence, and persistence of atopic dermatitis in adolescence: a prospective cohort study. J Allergy Clin Immunol. 2010;126:590-5.
68. Petrova SI, Berzhets VM, Albanova VI, Bystriskaia TF, Petrova NS. Immunotherapy in the complex treatment of patients with atopic dermatitis with sensitization to house dust mites. Zh Mikrobiol Epidemiol Immunobiol. 2006;1:33-6.
69. Pleskovic N, Bartholow A, Skoner DP. Sublingual immunotherapy in children: the recent experiences. Curr Opin Allergy Clin Immunol. 2014;14(6):582-90.
70. Qin YE, Mao JR, Sang YC, Li WX. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. Int J Dermatol. 2014;53:650-5.
71. Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol. 1982;107:597-602.
72. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol. 2011;131:67-73.
73. Silny W, Czarnecka-Operacz M, Silny P. Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiad Lek. 2005;58(5-6):287-94.
74. Silny W, Czarnecka-Operacz M, Silny P. Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis Part II. Evaluation of skin reactivity and concentration of serum antigen specific immunoglobulin E directed against selected airborne allergens. Wiad Lek. 2005;58(3-4):184-92.
75. Silny W, Czarnecka-Operacz M, Silny P. Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiad Lek. 2005;58(1-2):47-55.
76. Silny W, Czarnecka-Operacz M. Specific immunotherapy in the treatment of patients with atopic dermatitis-results of double blind placebo controlled study. Pol Merkur Lekarski. 2006;21(126):558-65. 88.
77. Slavyanskaya T. Derkach V Severe forms of atopic dermatitis in children: how to avoid complications? J Postgrad Med Education. 2014;4:47-8 [in Russian].
78. Slavyanskaya T, Derkach V, Sangidorj B. Atopic dermatitis in children: a combined immunotherapy complicated forms of the disease. Russian J Immunol. 2014;8(17):3. 727-29. [in Russian].
79. Slavyanskaya T, Derkach V, Sepiashvili R. Immunological and non-immunological pathogenetic mechanisms of development of complicated forms of atopic dermatitis (review). Georgian Med News. 2015;243:22-8. http://www.geomednews.org/shared/issues/med243.pdf.
80. Slavyanskaya T, Derkach V. Modern approaches to the management of moderate to severe atopic dermatitis in children. Allergology Immunol. 2015;16(2):219 [in Russian].
81. Slavyanskaya T, Derkach V. Clinical and immunologic characteristics of allergen-specific immunotherapy in children with atopic dermatitis. World Allergy Organization J. 2013;6(1):94.
82. Slavyanskaya T, Derkach V. Allergen-specific immunotherapy, as a pathogenetically justified method of treatment of children with atopic dermatitis. Allergy, Asthma & Immunophysiology: from basic sciences to clinical management». Medimond s.r.l. - Monduzzi Editore.- International Proceedings. 2013. p. 39-41. http://www.medimond.com/proceedings/moreinfo/20130427-index.pdf.
83. Slavyanskaya T, Derkach V, Sangidorj B. Atopic dermatitis in children: cost-effectiveness comparative estimation of various immunotropic therapy programmes. Ann Allergy Asthma Immunol. 2014;Suppl.1; 113(5):A113.
84. Sprecher E, Leung DY. Atopic dermatitis: scratching through the complexity of barrier dysfunction. J Allergy Clin Immunol. 2013;132:1130-31.
85. Stensen L, Thomsen SF, Backer V. Change in prevalence of atopic dermatitis between 1986 and 2001 among children. Allergy Asthma Proc. 2008;29:392-6.
86. Stock P, Rolinck-Werninghaus C, Wahn U, Hamelmann E. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis. BioDrugs. 2007;21(6):403-10.
87. Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet. 1996;347(8993):15-8.
88. Teplitsky V, Mumcuoglu KY, Babai I, Dalal I, Cohen R, Tanay A. House dust mites on skin, clothes, and bedding of atopic dermatitis patients. Int J Dermatol. 2008;47(8):790-5.
89. Thomas WR. House dust allergy and immunotherapy. Hum Vaccin Immunother. 2012;8(10):1469-78.
90. Treneva M, Pampura A. Antimicrobial peptides in the pathogenesis of atopic dermatitis. Russian J Perinatol Pediatr. 2011;2:80-4 [in Russian].
91. Trofimowicz A, Rzepecka E, Hofman J. Clinical effects of specific immunotherapy in children with atopic dermatitis. Rocz Akad Med Bialymst. 1995;40(2):414-22.
92. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet. 1978;2:912-15.
93. Werfel T, Zuberbier T. Diagnosis and treatment of atopic dermatitis in children and 96Allergy. Asthma and Immunology/PRACTALL Consensus Report Allergy. 2006;61(8):969-87.
94. Werfel T. The role of specific immunotherapy in atopic dermatitis. Drugs Today (Barc). 2008;44 Suppl B:47-9.
95. Zhang E, Tanaka T, Tajima M, et al. Characterization of the skin fungal microbiota in patients with atopic dermatitis and in healthy subjects. Microbiol Immunol. 2011;55(9):625-32.
96. Ziegler SF. Thymic stromal lymphopoietin and allergic disease. J Allergy Clin Immunol. 2012;130:845-52.